Oncimmune Regulatory News (ONC)

8 April 2022

Oncimmune Holdings plc

("Oncimmune" or the "Company")

Two further ImmunoINSIGHTS contracts signed

Projects with two US-based clinical-stage biopharmaceutical companies demonstrates the impact of the Company's new Commercial team

Oncimmune Holdings plc (AIM: ONC.L), the leading global immunodiagnostics group, today announces the signing of two new ImmunoINSIGHTS commercial contracts.

The first contract is with an US-based clinical-stage biopharmaceutical company which is developing first-in-class cellular immunotherapies for cancer patients utilizing off-the-shelf natural killer ("NK") cell and CAR-NK cell products. Under this contract, Oncimmune will utilize its specific high-throughput proprietary biomarker discovery platform, SeroTagTM, to identify autoantibodies that can be predictive of patient clinical response, and potential resistance to engineered cellular therapies in hematological and solid tumor oncology indications.

This new contract demonstrates the significant potential that the Company's ImmunoINSIGHTS technology platform could have in the engineered cellular therapy place.

The second contract signed is with a US-based clinical-stage biopharmaceutical company focused on developing a proprietary technology which harnesses the power of the immune system, to combat cancer by leveraging their proprietary technology to discover, develop and commercialize transformative oncology treatments. This project will profile the autoantibodies in patients treated with a virus-like particle which stimulates anti-tumor T cells. By profiling patients longitudinally, the aim of the project is to demonstrate how the immune system is affected by this therapy.

Dr Adam M Hill, CEO of Oncimmune said: "We are pleased to announce a further two contracts with our ImmunoINSIGHTS platform which demonstrates the progress that our Commercial team are making from our new US office in Boston. We are particularly excited by the signing of our first contract within the allogenic and CAR-NK market segment which we believe could open up a new opportunity for our services in the engineered cellular therapy space. Unlocking the utility of the ImmunoINSIGHTS platform in these cutting-edge therapies promises to substantially improve clinical outcomes for cancer patients."

For further information:

Oncimmune Holdings plc

Dr Adam M Hill, Chief Executive Officer

Matthew Hall, Chief Financial Officer

contact@oncimmune.co.uk

Singer Capital Markets (Nominated Adviser and Joint Broker)

Aubrey Powell, Harry Gooden, George Tzimas, James Fischer

+44 (0)20 7496 3000

WG Partners (Joint Broker)

David Wilson, Nigel Barnes, Erland Sternby

+44 (0)20 3705 9321

Media enquiries:

FTI Consulting

Ben Atwell, Michael Trace, Alex Davis

Oncimmune@fticonsulting.com

+44 (0)20 3727 1000

About Oncimmune

ImmunoINSIGHTS Service Business

Oncimmune is a leading immunodiagnostics developer, primarily focused on the growing fields of immuno-oncology, autoimmune disease and infectious diseases. The ImmunoINSIGHTS service business leverages Oncimmune's technology platform and methodologies across multiple diseases, to offer life-science organizations actionable insights for therapies across the development and product lifecycle. Our core immune-profiling technology is underpinned by our library of over eight thousand immunogenic proteins, one of the largest of its kind. This helps identify trial participants and patients into clinically relevant subgroups, enabling development of targeted and more effective treatments.

Oncimmune's ImmunoINSIGHTS service business is based at the Company's discovery research center in Dortmund, Germany. The business platform enables life science organizations to optimize drug development and delivery, leading to more effectively targeted and safer treatments for patients.

The ImmunoINSIGHTS development team is based in the US and Europe and Oncimmune is seeking to replicate the Dortmund facility in the US in the medium term.

EarlyCDT Product Business

Oncimmune's immunodiagnostic technology, EarlyCDT, can detect and help identify cancer on average four years earlier than standard clinical diagnosis. Our lead diagnostic test, EarlyCDT Lung, targets a vast market estimated to grow to £3.8bn by 2024. With over 200,000 tests already performed for patients worldwide and its use being supported by peer reviewed data in over 12,000 patients, we are poised to become an integral component of future lung cancer detection programs, globally.

Oncimmune's diagnostic products business is located at its laboratory facility in Nottingham, UK.

For more information, visit www.oncimmune.com

What is SeroTagTM?

Oncimmune's proprietary biomarker discovery engine, which is leveraged in our ImmunoINSIGHTS services to discover and validate novel biomarkers can help stratify patients in multiple cancer indications and with different autoimmune diseases.

This high-throughput, multiplex technology is based on one of the largest, in-house protein libraries, as well as a unique, ever-growing repository of disease data for indications including, but not limited to, autoimmune diseases and cancer. As a result, SeroTag is helping to address and monitor a number of challenges currently hindering the successful development and broader application of both cancer immunotherapies and treatments for autoimmune diseases.

The platform is being applied to discover and validate biomarkers and develop precision diagnostic tools from minimally invasive liquid biopsies. SeroTag analyzes autoantibodies-some of the most stable analytes-and is used most frequently for the identification of IgG isoforms, in addition to IgM and IgA, from just a few drops of serum.

The SeroTag platform acts as the primary discovery engine that feeds into the creation of Oncimmune's NavigAIDTM disease-specific stratification panels. These precision medicine tools which are enabling patient and disease stratification and support therapeutic development.